Valproic acid attenuates Aβ25-35-induced neurotoxicity in PC12 cells through suppression of mitochondria-mediated apoptotic pathway

Publication date: October 2018
Source:Biomedicine & Pharmacotherapy, Volume 106
Author(s): Li Zhao, Laiqing Zhu, Xiaoqian Guo
Aggregation of amyloid-β (Aβ) peptides is a pathological hallmark of Alzheimer's disease (AD). The purpose of the present study was to identify the protective role of valproic acid (VPA) against β-amyloid protein fragment 25–35 (Aβ25–35)-caused neurotoxicity in PC12 cells. Different doses of VPA was added to cultures of differentiated PC12 cells, 1 h before Aβ25–35. We found that VPA effectively prevented Aβ25–35-stimulated cytotoxicity through attenuating apoptosis and increasing the ratio of Bcl-2/Bax in PC12 cells. VPA also significantly inhibited the generation of ROS induced by Aβ25–35 in PC12 cells in a dose-dependent manner. In addition, VPA significantly alleviated mitochondrial dysfunction through improvement of mitochondrial membrane potential, inhibition of cytochrome c release, and promotion of mitochondrial ATP synthesis. Furthermore, VPA treatment reduced the expression levels of proinflammatory cytokines and attenuated the activation of NF-κB signaling. In conclusion, our results suggested that VPA might serve as a novel protective agent against Aβ25–35-induced cytotoxicity in AD.



https://ift.tt/2lGpMuh